Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Liraglutide

SCALE™ IBT

Novo Nordisk · Phase 3 · Completed · Enrollment 282

NCT02963935

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

X axis: threshold category. Y axis: participants reaching threshold, %.

61.4738.82
≥5%
30.4519.75
≥10%
18.118.92
≥15%
≥20%
Show as table
Arm≥5%≥10%≥15%≥20%
Liraglutiden/rn/rn/rn/r
Placebon/rn/rn/rn/r
Liraglutide 3.0 mg, in trial61.47%30.45%18.11%n/r
Placebo, in trial38.82%19.75%8.92%n/r

Not shown

  • Liraglutide: endpoint not reported
  • Placebo: endpoint not reported